Baseline characteristics of the included studies.

<div><p>Background</p><p>PD-1/PD-L1 inhibitors (PI) have shown promising results in both neoadjuvant and adjuvant therapies for resectable non-small cell lung cancer (NSCLC). However, substantial evidence from large-scale studies is still lacking for their use in the perioper...

Full description

Saved in:

Bibliographic Details
Main Author:	Hai Huang (140371) (author)
Other Authors:	Lianyun Li (3435095) (author), Ling Tong (632992) (author), Houfu Luo (19727416) (author), Huijing Luo (19727419) (author), Qimin Zhang (17692601) (author)
Published:	2024
Subjects:	Biochemistry Medicine Cell Biology Pharmacology Biotechnology Developmental Biology Cancer treatment discontinuations due shown promising results 6 &# 8211 12 &# 8211 major pathological response significantly improve survival prolonged survival times ppi group experienced 5 aes must rr ]: 5 77 ]), event xlink "> pd hr ]: 0 xlink "> 5 aes pathological responses serious aes free survival substantial evidence still lacking seen across scale studies risk ratio resectable nsclc resectable non rcts ), r0 resections primary endpoint ppi cohort perioperative setting perioperative pd nsclc ). l1 inhibitors increased incidence hazard ratio analysis based analysis aims adverse events adjuvant therapies 82 ]). 57 ]), 48 months
Tags:	Add Tag No Tags, Be the first to tag this record!

Baseline characteristics of the included studies.

Similar Items